Structured population data were available for 3 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 2 studies described adult participants.

1 supporting study has high, serious, critical, unclear, or unavailable risk-of-bias information.

1 study contains conflicting p-value and significance fields; those significance claims are suppressed.

Placebo Group

Core clinician-reference fields are available or not applicable.

Participants received 1500 mg of curcumin daily for 12 months.

Curcumin Group

In this 12-month, randomized, double-blind, placebo-controlled trial, 227 obese individuals with T2DM were assigned to receive either 1500 mg of curcumin daily or placebo.

Participants received placebo capsules for 12 months.

Participants ingested three blinded capsules of either curcumin (250 mg of curcuminoids per capsule) or placebo twice daily (six capsules per day) for 12 months.

Curcumin improves liver health in obese diabetes patients

Participants received curcumin capsules daily for 12 weeks.

Eligible participants were randomly assigned to receive either a placebo or a curcumin capsule daily for 12 weeks.

Participants received placebo capsules daily for 12 weeks.

Curcumin may improve glucose control in older adults with prediabetes

Participants received 1500 mg/day curcumin supplementation for 12 months.

This randomized, double-blind, placebo-controlled trial evaluated the effects of 1500 mg/day curcumin supplementation for 12 months in 114 adults with T2DM.

Participants received a placebo treatment for 12 months.

Curcumin supplementation was associated with significant reductions compared with placebo.

Authoritative quality diagnostic: p value significance conflict.

Curcumin supplementation × HbA1c

Available supporting studies

Curcumin improves liver health in obese diabetes patients

Curcumin may improve glucose control in older adults with prediabetes

Curcumin may improve inflammation and glycemic control in diabetes